z-logo
open-access-imgOpen Access
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study
Author(s) -
Lambert Assoumou,
C. Charpentier,
Patricia RecordonPinson,
Maxime Grudé,
C. Pallier,
Laurence MorandJoubert,
Samira FafiKremer,
Anne Krivine,
Brigitte Montès,
Virginie Ferré,
Magali Bouvier–Alias,
JeanChristophe Plantier,
Jacques Izopet,
MaryAnne Trabaud,
Sabine Yerly,
Jacqueline Dufayard,
Chakib Alloui,
Laurence Courdavault,
Hélène Le GuillouGuillemette,
Anne Maillard,
Corinne Amiel,
Astrid Vabret,
Catherine Roussel,
Sophie Vallet,
Jérôme Guinard,
Audrey Mirand,
A. BebyDefaux,
Francis Barin,
A Allardet-Servent,
Rachid Ait-Namane,
Marc Wirden,
Constance Delaugerre,
Vincent Cálvez,
MarieLaure Chaix,
Diane Descamps,
Sandrine Reigadas
Publication year - 2017
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkx042
Subject(s) - integrase , drug resistance , genotyping , viral load , virology , medicine , hiv drug resistance , integrase inhibitor , reverse transcriptase , lentivirus , human immunodeficiency virus (hiv) , protease , protease inhibitor (pharmacology) , antiretroviral therapy , genotype , viral disease , biology , polymerase chain reaction , microbiology and biotechnology , gene , enzyme , genetics , biochemistry
Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom